Cargando…
Managing chronic myeloid leukemia patients intolerant to tyrosine kinase inhibitor therapy
The outcomes for patients with chronic myeloid leukemia have improved dramatically with the development and availability of BCR–ABL1 tyrosine kinase inhibitors (TKIs) over the past decade. TKI therapy has a superior safety profile compared with the previous standard of care, interferon-α, and most a...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3483619/ https://www.ncbi.nlm.nih.gov/pubmed/23085780 http://dx.doi.org/10.1038/bcj.2012.30 |